Therapy appears to reduce rate of chemotherapy-induced early menopause for women with breast cancer

July 19, 2011 in Cancer

Temporarily suppressing ovarian function with use of the hormone analogue triptorelin reduced the occurrence of early menopause induced by chemotherapy among women with breast cancer, according to a study in the July 20 issue of JAMA.

Approximately 6 percent of women with are diagnosed before age 40 years, with the majority of young patients receiving systemic treatment with chemotherapy, , or both. Chemotherapy regimens are associated with an incidence of long-term amenorrhea (absence of menstruation) of at least 40 percent, according to background information in the article. No standard strategies for preventing chemotherapy-induced ovarian failure are yet available. Preclinical data have suggested that temporary ovarian suppression with a gonadotropin (hormones that are secreted by the )-releasing hormone (GnRH) analogue () during chemotherapy reduces ovarian toxicity.

Lucia Del Mastro, M.D., of the Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, and colleagues conducted a phase 3 trial designed to assess the efficacy of temporary ovarian suppression induced by the GnRH analogue triptorelin in reducing the incidence of in young women with breast cancer undergoing supplemental or neoadjuvant (i.e., administered before surgery for breast cancer) chemotherapy. The was conducted at 16 sites in Italy and enrolled 281 patients between October 2003 and January 2008. The patients were with stage I through III breast cancer who were candidates for or neoadjuvant chemotherapy. Before beginning chemotherapy, patients were randomly allocated to receive chemotherapy alone or combined with triptorelin, which was administered intramuscularly at least 1 week before the start of chemotherapy and then every 4 weeks for the duration of chemotherapy.

After the patients received treatment as indicated in the trial, the researchers found that the rate of early menopause was 25.9 percent in the chemotherapy-alone group and 8.9 percent in the chemotherapy plus triptorelin group, an absolute difference of 17 percent. The number needed to treat (i.e., the number of patients that need to be treated with triptorelin to prevent early menopause in 1 patient) was 6. Further analysis showed that only treatment with triptorelin was associated with a significant reduction of the risk of developing early menopause. Patient age and the type of chemotherapy did not significantly affect the risk.

Resumption of menses was observed in 60 patients in the chemotherapy-alone group (49.6 percent) and in 88 in the chemotherapy plus triptorelin group (63.3 percent).

"In conclusion, our results suggest that temporarily suppressing ovarian function by administering triptorelin reduces the incidence of chemotherapy-induced early menopause. This treatment can therefore be offered to premenopausal patients with breast cancer who wish to decrease the risk of permanent ovarian failure associated with chemotherapy," the authors write.

Editorial: Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer

In an accompanying editorial, Hope S. Rugo, M.D., and Mitchell P. Rosen, M.D., of the University of California, San Francisco, write that the data reported in this study represent an important and encouraging addition to the study of ovarian preservation for women in this difficult situation.

"Given that patients with hormone receptor-positive disease in the current study who had evidence of ovarian recovery were immediately suppressed without data on long-term recovery and that breast cancer outcome data are not available, and given as well the potential adverse effects on disease outcome, the use of GnRH agonists concomitant [at the same time] with chemotherapy cannot be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease."

"International guidelines recommend discussion of fertility options before starting chemotherapy, and when possible before surgery, to allow optimal timing for consultation and oocyte [egg cell] harvesting. When feasible, and for with hormone-insensitive disease, GnRH agonist therapy to suppress ovarian function during is an additional treatment that can potentially expand fertility possibilities. Although recovering menses is not the same as fertility preservation, it is one step in the right direction."

More information: Paper: JAMA. 2011;306[3]269-276. Editorial: JAMA. 2011;306[3]312-314.

Provided by JAMA and Archives Journals search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Older prostate cancer patients should think twice before undergoing treatment

Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...

Cancer created 9 hours ago | popularity not rated yet | comments 0 | with audio podcast

Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...

Cancer created 11 hours ago | popularity not rated yet | comments 0

The compound in the Mediterranean diet that makes cancer cells 'mortal'

New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death. By altering a very specific step in gene regulation, this compound essentially re-educates cancer ...

Cancer created 12 hours ago | popularity 4.8 / 5 (11) | comments 2 | with audio podcast

CT radiation risk less than risk of examination indicator

(HealthDay)—For young adults needing either a chest or abdominopelvic computed tomography (CT), the short-term risk of death from underlying morbidity is greater than the long-term risk of radiation-induced ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Team finds mechanism linking key inflammatory marker to cancer

In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.

Cancer created 18 hours ago | popularity not rated yet | comments 0 | with audio podcast


New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Early-life traffic-related air pollution exposure linked to hyperactivity

Early-life exposure to traffic-related air pollution was significantly associated with higher hyperactivity scores at age 7, according to new research from the University of Cincinnati (UC) and Cincinnati Children's Hospital ...

Do salamanders hold the solution to regeneration?

Salamanders' immune systems are key to their remarkable ability to regrow limbs, and could also underpin their ability to regenerate spinal cords, brain tissue and even parts of their hearts, scientists have ...

Scientists identify molecular trigger for Alzheimer's disease

Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons ...

Resistance to last-line antibiotic makes bacteria resistant to immune system

Bacteria resistant to the antibiotic colistin are also commonly resistant to antimicrobial substances made by the human body, according to a study in mBio, the online open-access journal of the American Society for Microb ...

Practice makes perfect? Not so much

Turns out, that old "practice makes perfect" adage may be overblown. New research led by Michigan State University's Zach Hambrick finds that a copious amount of practice is not enough to explain why people ...